Cryoglobulinemia and double‐filtration plasmapheresis : Personal experience and literature review
Abstract Background Cryoglobulinemia is defined as the presence of an abnormal immunoglobulin that may be responsible for vasculitis of small‐caliber vessels. Apheresis can be used in order to temporarily eliminate circulating cryoglobulins. The aim of this study was to assess the effectiveness of apheresis (double‐filtration plasmapheresis‐DFPP‐) in symptomatic and/or severe cryoglobulinemias. Methods Four male patients presenting cryoglobulinemic vasculitis and who received DFPP sessions were included. Results Their mean age was 57 ± 15 years. One patient had hepatitis‐C virus (HCV)‐related cryoglobulinemia and the other three patients were carriers of an IgM Kappa monoclonal gammopathy. Mean duration of follow‐up was 15 ± 2 months. DFPP allowed healing of ulcerative skin lesions in the first patient and remission of nephrotic syndrome in the other patients after a median of 6(5–10) sessions. Conclusion DFPP can be used safely in cryoglobulinemic‐vasculitis and can be considered early to achieve a faster and sustained clinical‐biological response..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Therapeutic Apheresis and Dialysis - 27(2023), 1, Seite 159-169 |
| Beteiligte Personen: |
Naciri Bennani, Hamza [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 International Society for Apheresis and Japanese Society for Apheresis |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1111/1744-9987.13885 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY013692755 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY013692755 | ||
| 003 | DE-627 | ||
| 005 | 20231111203104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230221s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/1744-9987.13885 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_TAP_2023_27_1.zip.xml |
| 035 | |a (DE-627)WLY013692755 | ||
| 035 | |a (WILEY)TAP13885 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Naciri Bennani, Hamza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cryoglobulinemia and double‐filtration plasmapheresis |b Personal experience and literature review |
| 264 | 1 | |c 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 International Society for Apheresis and Japanese Society for Apheresis | ||
| 520 | |a Abstract Background Cryoglobulinemia is defined as the presence of an abnormal immunoglobulin that may be responsible for vasculitis of small‐caliber vessels. Apheresis can be used in order to temporarily eliminate circulating cryoglobulins. The aim of this study was to assess the effectiveness of apheresis (double‐filtration plasmapheresis‐DFPP‐) in symptomatic and/or severe cryoglobulinemias. Methods Four male patients presenting cryoglobulinemic vasculitis and who received DFPP sessions were included. Results Their mean age was 57 ± 15 years. One patient had hepatitis‐C virus (HCV)‐related cryoglobulinemia and the other three patients were carriers of an IgM Kappa monoclonal gammopathy. Mean duration of follow‐up was 15 ± 2 months. DFPP allowed healing of ulcerative skin lesions in the first patient and remission of nephrotic syndrome in the other patients after a median of 6(5–10) sessions. Conclusion DFPP can be used safely in cryoglobulinemic‐vasculitis and can be considered early to achieve a faster and sustained clinical‐biological response. | ||
| 700 | 1 | |a Banza, Augustin Twite |4 aut | |
| 700 | 1 | |a Terrec, Florian |4 aut | |
| 700 | 1 | |a Noble, Johan |4 aut | |
| 700 | 1 | |a Jouve, Thomas |4 aut | |
| 700 | 1 | |a Motte, Lionel |4 aut | |
| 700 | 1 | |a Malvezzi, Paolo |4 aut | |
| 700 | 1 | |a Rostaing, Lionel |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Apheresis and Dialysis |g 27(2023), 1, Seite 159-169 |w (DE-627)WLY013687417 |x 17449987 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:1 |g pages:159-169 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 1 |h 159-169 |g 11 | ||